Skip to content
Screener

Arbutus Biopharma Corporation ABUS Price / earnings

Price / earnings at other companies

Arrowhead Research logo
Arrowhead ResearchARWR
44.6×—
Gilead Sciences logo
Gilead SciencesGILD
18.8×-4.6×
ALN
Alnylam PharmaceuticalsALNY
54.8×—
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
1.2×—
AbbVie logo
AbbVieABBV
70.5×-16.6×
Lantheus Holdings logo
Lantheus HoldingsLNTH
26.2×+6.4×

Other financials

Income statement

See full
Revenue$179.1M+10,055%
Operating income$168.9M+757%
Net income$169.7M+792%
EPS (diluted)$0.87+769%

Balance sheet

See full
Cash & equivalents$23.7M-36.1%
Total debt$631.0K-46.9%
Total equity$260.2M+229%
Total assets$277.2M+137%

Cash flow

See full
Operating cash flow-$8.1M+39.4%
CapEx--100%
Free cash flow-$4.7M+55.0%

Valuation

See full
Market cap$896.82M+42.4%
Enterprise value$873.75M+47.1%
P/S4.7×-36.1×

Profitability

See full
Operating margin81.7%+42.1pp
Net margin84%+43.4pp
FCF margin-281.5%-119pp

Returns & leverage

See full
Return on equity94.7%+65.1pp
Debt / equity0×0.0×
Current ratio54.3×+48.3×

Where this comes from

Calculated from Arbutus Biopharma Corporation’s reported figures.

market cap/net income=5.5×

Based on the most recent quarter.

The source filing: Arbutus Biopharma Corporation’s 10-Q, filed May 13, 2026. Open the filing →

Filed
May 13, 2026, 7:31 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001447028-26-000021

FAQ

What is Arbutus Biopharma Corporation's price / earnings?
Arbutus Biopharma Corporation (ABUS) reported price / earnings of 5.5× in Q1 2026.
What does price / earnings mean?
Market capitalization at the quarter end divided by trailing-twelve-month net income. The price the market pays for each dollar of trailing earnings.

Ask your AI about Arbutus Biopharma Corporation's price / earnings.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude